Modulation of cell cycle control by vitamin D3 and its analogue, EB1089, in human breast cancer cells

Gengfei Wu, Robert S. Fan, Wenhui Li, Tien C. Ko, Michael G. Brattain

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Examination of a panel of ER positive breast cancer cell lines showed that they were differentially growth inhibited by vitamin D3 and its analogue EB1089. EB1089 treatment of the breast cancer cell lines MCF- 7 E, BT20, T47D, and ZR75 demonstrated a correlation between a reduction in Cdk2 kinase activity towards phosphorylation of histone H1 and a decrease in DNA synthesis, while no modulation of CdkZ activity was observed in the vitamin D3 and EB1089 resistant cell line MCF-7 L. This was accompanied by a time dependent decrease in the percentage of S phase cells in the responsive lines. Characterization of the expression levels of Cdk2 and its related cell cycle proteins in MCF-7 E cells showed that after EB1089 treatment, there was a concentration and time dependent up-regulation of p21 as well as a decrease in cyclin A proteins. Paradoxically, cyclin E levels were increased as a function of treatment. Analysis of cyclin-Cdk2-Cdki complex formation showed that in EB1089 treated MCF-7 E cells, Cdk2, cyclin A and cyclin E immunoprecipitates contained an increased abundance of p21. In contrast to MCF-7 E cells, increases in both p21 and p27 as well as their complex formation with Cdk2 were observed in BT20 and ZR75 cells. These findings indicate that up-regulation of p21 as well as p27 in some cell types may account for the inactivation of Cdk2 activity and a G1 block of the cell cycle following EB1089 treatment.

Original languageEnglish (US)
Pages (from-to)1555-1563
Number of pages9
JournalOncogene
Volume15
Issue number13
DOIs
StatePublished - Jan 1 1997

Fingerprint

Cholecalciferol
Cell Cycle Checkpoints
Breast Neoplasms
MCF-7 Cells
Cyclin A
Cyclin E
Cell Line
Up-Regulation
Cell Cycle Proteins
Cyclins
S Phase
Histones
seocalcitol
Cell Cycle
Phosphotransferases
Phosphorylation
DNA
Growth
Proteins

Keywords

  • Breast cancer
  • EB1089
  • Inactivation of Cdk2 activity
  • Vitamin D
  • p21(WAF-1/CIP-1)

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Modulation of cell cycle control by vitamin D3 and its analogue, EB1089, in human breast cancer cells. / Wu, Gengfei; Fan, Robert S.; Li, Wenhui; Ko, Tien C.; Brattain, Michael G.

In: Oncogene, Vol. 15, No. 13, 01.01.1997, p. 1555-1563.

Research output: Contribution to journalArticle

Wu, Gengfei ; Fan, Robert S. ; Li, Wenhui ; Ko, Tien C. ; Brattain, Michael G. / Modulation of cell cycle control by vitamin D3 and its analogue, EB1089, in human breast cancer cells. In: Oncogene. 1997 ; Vol. 15, No. 13. pp. 1555-1563.
@article{e97316beadc64f18a025e67b084bf5aa,
title = "Modulation of cell cycle control by vitamin D3 and its analogue, EB1089, in human breast cancer cells",
abstract = "Examination of a panel of ER positive breast cancer cell lines showed that they were differentially growth inhibited by vitamin D3 and its analogue EB1089. EB1089 treatment of the breast cancer cell lines MCF- 7 E, BT20, T47D, and ZR75 demonstrated a correlation between a reduction in Cdk2 kinase activity towards phosphorylation of histone H1 and a decrease in DNA synthesis, while no modulation of CdkZ activity was observed in the vitamin D3 and EB1089 resistant cell line MCF-7 L. This was accompanied by a time dependent decrease in the percentage of S phase cells in the responsive lines. Characterization of the expression levels of Cdk2 and its related cell cycle proteins in MCF-7 E cells showed that after EB1089 treatment, there was a concentration and time dependent up-regulation of p21 as well as a decrease in cyclin A proteins. Paradoxically, cyclin E levels were increased as a function of treatment. Analysis of cyclin-Cdk2-Cdki complex formation showed that in EB1089 treated MCF-7 E cells, Cdk2, cyclin A and cyclin E immunoprecipitates contained an increased abundance of p21. In contrast to MCF-7 E cells, increases in both p21 and p27 as well as their complex formation with Cdk2 were observed in BT20 and ZR75 cells. These findings indicate that up-regulation of p21 as well as p27 in some cell types may account for the inactivation of Cdk2 activity and a G1 block of the cell cycle following EB1089 treatment.",
keywords = "Breast cancer, EB1089, Inactivation of Cdk2 activity, Vitamin D, p21(WAF-1/CIP-1)",
author = "Gengfei Wu and Fan, {Robert S.} and Wenhui Li and Ko, {Tien C.} and Brattain, {Michael G.}",
year = "1997",
month = "1",
day = "1",
doi = "10.1038/sj.onc.1201329",
language = "English (US)",
volume = "15",
pages = "1555--1563",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "13",

}

TY - JOUR

T1 - Modulation of cell cycle control by vitamin D3 and its analogue, EB1089, in human breast cancer cells

AU - Wu, Gengfei

AU - Fan, Robert S.

AU - Li, Wenhui

AU - Ko, Tien C.

AU - Brattain, Michael G.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Examination of a panel of ER positive breast cancer cell lines showed that they were differentially growth inhibited by vitamin D3 and its analogue EB1089. EB1089 treatment of the breast cancer cell lines MCF- 7 E, BT20, T47D, and ZR75 demonstrated a correlation between a reduction in Cdk2 kinase activity towards phosphorylation of histone H1 and a decrease in DNA synthesis, while no modulation of CdkZ activity was observed in the vitamin D3 and EB1089 resistant cell line MCF-7 L. This was accompanied by a time dependent decrease in the percentage of S phase cells in the responsive lines. Characterization of the expression levels of Cdk2 and its related cell cycle proteins in MCF-7 E cells showed that after EB1089 treatment, there was a concentration and time dependent up-regulation of p21 as well as a decrease in cyclin A proteins. Paradoxically, cyclin E levels were increased as a function of treatment. Analysis of cyclin-Cdk2-Cdki complex formation showed that in EB1089 treated MCF-7 E cells, Cdk2, cyclin A and cyclin E immunoprecipitates contained an increased abundance of p21. In contrast to MCF-7 E cells, increases in both p21 and p27 as well as their complex formation with Cdk2 were observed in BT20 and ZR75 cells. These findings indicate that up-regulation of p21 as well as p27 in some cell types may account for the inactivation of Cdk2 activity and a G1 block of the cell cycle following EB1089 treatment.

AB - Examination of a panel of ER positive breast cancer cell lines showed that they were differentially growth inhibited by vitamin D3 and its analogue EB1089. EB1089 treatment of the breast cancer cell lines MCF- 7 E, BT20, T47D, and ZR75 demonstrated a correlation between a reduction in Cdk2 kinase activity towards phosphorylation of histone H1 and a decrease in DNA synthesis, while no modulation of CdkZ activity was observed in the vitamin D3 and EB1089 resistant cell line MCF-7 L. This was accompanied by a time dependent decrease in the percentage of S phase cells in the responsive lines. Characterization of the expression levels of Cdk2 and its related cell cycle proteins in MCF-7 E cells showed that after EB1089 treatment, there was a concentration and time dependent up-regulation of p21 as well as a decrease in cyclin A proteins. Paradoxically, cyclin E levels were increased as a function of treatment. Analysis of cyclin-Cdk2-Cdki complex formation showed that in EB1089 treated MCF-7 E cells, Cdk2, cyclin A and cyclin E immunoprecipitates contained an increased abundance of p21. In contrast to MCF-7 E cells, increases in both p21 and p27 as well as their complex formation with Cdk2 were observed in BT20 and ZR75 cells. These findings indicate that up-regulation of p21 as well as p27 in some cell types may account for the inactivation of Cdk2 activity and a G1 block of the cell cycle following EB1089 treatment.

KW - Breast cancer

KW - EB1089

KW - Inactivation of Cdk2 activity

KW - Vitamin D

KW - p21(WAF-1/CIP-1)

UR - http://www.scopus.com/inward/record.url?scp=0030699254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030699254&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1201329

DO - 10.1038/sj.onc.1201329

M3 - Article

C2 - 9380407

AN - SCOPUS:0030699254

VL - 15

SP - 1555

EP - 1563

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 13

ER -